Everolimus Related Pneumonitis in MBC

Completed

• Conditions: Pneumonitis; Everolimus

• Registration Number: NCT03730428
• Lead Sponsor: Fudan University

Brief Summary

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-07-15
• Study First Submitted: 2018-11-02
• Study First Submitted QC: 2018-11-02
• Study First Posted: 2018-11-05
• Primary Completion: 2020-05-15
• Study Completion: 2020-06-15
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-16
• Last Update Posted: 2020-08-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer
2. Treated with everolimus for at least one month in metastatic setting
3. With baseline and at least one follow-up chest CT during everolimus therapy.
4. Complete medical history

Read More

Exclusion Criteria

1. Incomplete medical history
2. Radiographic imaging unavailable

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
radiographic pattern	2 months	Quantitive measure of lung CT
PFS	2 months	Progression free survival

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China